Siemens Healthineers (OTCMKTS:SMMNY) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Siemens Healthineers (OTCMKTS:SMMNY) from a strong sell rating to a hold rating in a report released on Monday morning,Zacks.com reports.

SMMNY has been the topic of several other reports. Royal Bank Of Canada began coverage on Siemens Healthineers in a report on Wednesday, December 17th. They set a “moderate buy” rating on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Siemens Healthineers from a “buy” rating to a “hold” rating in a research note on Thursday, December 4th. Three research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Siemens Healthineers presently has an average rating of “Buy”.

Siemens Healthineers Stock Up 0.8%

Shares of SMMNY traded up $0.22 during mid-day trading on Monday, hitting $27.39. 3,388 shares of the company’s stock were exchanged, compared to its average volume of 69,067. Siemens Healthineers has a 52 week low of $23.28 and a 52 week high of $30.19. The stock’s 50-day simple moving average is $25.55 and its 200-day simple moving average is $26.85.

Siemens Healthineers Company Profile

Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.

The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.